Reliable business case for repurposing of existing medicines requires key changes in government policies

Affiliations

¹ Centre for Future Affordable and Sustainable Therapy Development (FAST), the Hague, the Netherlands; Medicines for Society (Medicijn voor de Maatschappij), Platform at Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: saco.devisser@fast.nl.
² Medicines for Society (Medicijn voor de Maatschappij), Platform at Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; Department of Endocrinology and Metabolism, Amsterdam UMC, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM) Research Institute, University of Amsterdam, Amsterdam, the Netherlands.
³ Department of Cardiology, Meander Medical Centre, Amersfoort, the Netherlands.
⁴ European Infrastructure for Translational Medicine (EATRIS), Amsterdam, the Netherlands.

Editorial

Samuel J de Visser et al. Drug Discov Today. 2024 Sep.

. 2024 Sep;29(9):104096.

doi: 10.1016/j.drudis.2024.104096. Epub 2024 Jul 9.

¹ Centre for Future Affordable and Sustainable Therapy Development (FAST), the Hague, the Netherlands; Medicines for Society (Medicijn voor de Maatschappij), Platform at Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: saco.devisser@fast.nl.
² Medicines for Society (Medicijn voor de Maatschappij), Platform at Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; Department of Endocrinology and Metabolism, Amsterdam UMC, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM) Research Institute, University of Amsterdam, Amsterdam, the Netherlands.
³ Department of Cardiology, Meander Medical Centre, Amersfoort, the Netherlands.
⁴ European Infrastructure for Translational Medicine (EATRIS), Amsterdam, the Netherlands.

No abstract available

Publication types